Bioage Labs, Inc. (BIOA) fundamentals score
Bioage Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. Its technology platform and differentiated human datasets enable it to identify promising targets based on insights into molecular changes that drive aging.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 5.1 out of 10, Mixed fundamentals
- Growth: 5.5/10
- Profitability: 3.3/10
- Financial health: 6.8/10
- Earnings quality: 4.6/10
- Valuation: 5.5/10
Scores are calculated from Bioage Labs, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10